Nuclear GAPDH cascade mediates pathological cardiac hypertrophy

Pathological stressors disrupt cellular homeostasis, causing various diseases. We report a non-glycolytic role for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the pathological growth response of the heart. In cellular and animal models for cardiac hypertrophy, nuclear translocation of GAPDH was elicited in cardiac myocytes, followed by activation of p300 histone acetyl-transferase (HAT), an inducer of heart hypertrophy gene programs. The hypertrophy was inhibited by a compound antagonizing the nuclear GAPDH cascade. In mice with selective deletion of GAPDH’s nuclear function in cardiac myocytes, the stress-induced cardiac hypertrophy and functional deficits were normalized. Nuclear GAPDH cascade plays a pivotal role in stress response/homeostatic control in the heart. GAPDH may act as a key homeostatic mediator in living organisms through its stress-responsive nuclear translation. One-sentence summary Non-glycolytic function of GAPDH critically regulates heart homeostasis and mediates cardiac pathological hypertrophy

[1]  Peter A. Calabresi,et al.  Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity , 2018, Science.

[2]  A. Ferry,et al.  Voluntary Exercise Improves Cardiac Function and Prevents Cardiac Remodeling in a Mouse Model of Dilated Cardiomyopathy , 2017, Front. Physiol..

[3]  B. Faubert,et al.  Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis , 2013, Cell.

[4]  F. Saudou,et al.  Vesicular Glycolysis Provides On-Board Energy for Fast Axonal Transport , 2013, Cell.

[5]  M. Bristow.  Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. , 2011, Circulation research.

[6]  M. Sirover.  On the functional diversity of glyceraldehyde-3-phosphate dehydrogenase: biochemical mechanisms and regulatory control. , 2011, Biochimica et biophysica acta.

[7]  A. Sawa,et al.  The diverse functions of GAPDH: views from different subcellular compartments. , 2011, Cellular signalling.

[8]  Dong I. Lee,et al.  Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. , 2010, Journal of the American College of Cardiology.

[9]  D. Malone,et al.  MAO inhibitors: Risks, benefits, and lore , 2010, Cleveland Clinic Journal of Medicine.

[10]  K. Liestøl,et al.  Reference gene alternatives to Gapdh in rodent and human heart failure gene expression studies , 2010, BMC Molecular Biology.

[11]  D. Kass,et al.  Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. , 2009, The Journal of clinical investigation.

[12]  K. Webster,et al.  Quantitative Control of Adaptive Cardiac Hypertrophy by Acetyltransferase p300 , 2008, Circulation.

[13]  S. Snyder,et al.  Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis , 2008, Nature Cell Biology.

[14]  S. Vatner,et al.  A Redox-Dependent Pathway for Regulating Class II HDACs and Cardiac Hypertrophy , 2008, Cell.

[15]  Da-Zhi Wang,et al.  The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. , 2008, The Journal of clinical investigation.

[16]  E. Olson,et al.  Cardiac plasticity. , 2008, The New England journal of medicine.

[17]  Stefan Neubauer,et al.  The failing heart--an engine out of fuel. , 2007, The New England journal of medicine.

[18]  D. Kass,et al.  Role of oxidative stress in cardiac hypertrophy and remodeling. , 2007, Hypertension.

[19]  A. Sawa,et al.  GAPDH as a sensor of NO stress. , 2006, Biochimica et biophysica acta.

[20]  Akira Sawa,et al.  Neuroprotection by pharmacologic blockade of the GAPDH death cascade. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Snyder,et al.  S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding , 2005, Nature Cell Biology.

[22]  G. Dorn,et al.  Protein kinase cascades in the regulation of cardiac hypertrophy. , 2005, The Journal of clinical investigation.

[23]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[24]  D. Chuang,et al.  Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases. , 2005, Annual review of pharmacology and toxicology.

[25]  R. Roeder,et al.  Regulation of the p300 HAT domain via a novel activation loop , 2004, Nature Structural &Molecular Biology.

[26]  H. Wada,et al.  Biological role of p300 in cardiac myocytes , 2003, Molecular and Cellular Biochemistry.

[27]  Y. Horiguchi,et al.  Super acid-induced Pummerer-type cyclization reaction: improvement in the synthesis of chiral 1,3-dimethyl-1,2,3,4-tetrahydroisoquinolines. , 2003, Chemical & pharmaceutical bulletin.

[28]  Ian M Adcock,et al.  The Transcriptional Co-activators CREB-binding Protein (CBP) and p300 Play a Critical Role in Cardiac Hypertrophy That Is Dependent on Their Histone Acetyltransferase Activity* , 2003, The Journal of Biological Chemistry.

[29]  K. Chien,et al.  Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gαq/Gα11 in cardiomyocytes , 2001, Nature Medicine.

[30]  R. Nilakantan,et al.  6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. , 2001, Journal of medicinal chemistry.

[31]  K. Webster,et al.  Control of Cardiac-specific Transcription by p300 through Myocyte Enhancer Factor-2D* , 2001, The Journal of Biological Chemistry.

[32]  K. Chien,et al.  Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. , 2001, Nature medicine.

[33]  北村 聖.  "The New England Journal of Medicine". , 1962, British medical journal.